MDM2 and breast cancer: On the other hand, AKT activation and p53 attenuation may have already been well-achieved and maintained in breast cancer cells, which mostly occur in cytoplasm, and the regulation of YY1 in promoting AKT activation and MDM2-mediated p53 degradation may not be prominently required at this stage.